ERC-1671 is under clinical development by ERC Belgium and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM).

SurVaxM is under clinical development by MimiVax and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase ...

A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial. The vaccine – developed by researchers at the ...

Russia has reportedly developed a vaccine against cancer that it will launch early next year. The jab, which will be free of cost, will treat patients instead of preventing the disease in the general ...

The vaccine also exhibited a favorable tolerability profile, with no dose-limiting toxicities reported. Early efficacy data from the CVGBM trial in glioblastoma patients revealed one partial ...

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...

The vaccine also exhibited a favorable tolerability profile, with no dose-limiting toxicities reported. Early efficacy data from the CVGBM trial in glioblastoma patients revealed one partial response ...

Fox News commentator Kelly Powers died in December after battling brain cancer for more than four years, contrary to posts ...

"Russia has developed its own mRNA vaccine against cancer, it will be distributed to patients free of charge, General ...

Fox News health commentator Dr. Kelly Powers was diagnosed with glioblastoma, an aggressive form of brain cancer, in July 2020, months before COVID-19 vaccines were made available in the U.S. But ...

In a recent phase 3 study, an autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) was shown to extend survival in patients with glioblastoma. When added to standard of care ...

In the United States, researchers at the University of Florida recently tested an individualised vaccine on patients with glioblastoma, an aggressive form of brain cancer. The vaccine showed promising ...